Q1 2026 results set the tone

Sight Sciences (SGHT) has opened 2026 with Q1 revenue of US$19.7 million and a basic EPS loss of US$0.24, alongside trailing twelve month revenue of US$79.6 million and a basic EPS loss of US$0.71 that keeps the story firmly in loss-making territory. The company has seen quarterly revenue move from US$17.5 million in Q1 2025 to US$19.7 million in Q1 2026. Quarterly basic EPS has ranged from a loss of US$0.28 in Q1 2025 to a loss of US$0.08 in Q4 2025 and a loss of US$0.24 this quarter, setting up an earnings season where investors are focused on how quickly margins can move toward breakeven.

See our full analysis for Sight Sciences.

With the headline numbers on the table, the next step is to see how this earnings print lines up with the main narratives around Sight Sciences, and where the data challenges what investors have come to expect.

Losses still heavy at US$37.3 million over 12 months

• On a trailing twelve month basis, Sight Sciences reported net income excluding extra items of a loss of US$37.3 million and basic EPS of a loss of US$0.71, compared with a Q1 2026 quarterly loss of US$13.0 million and basic EPS of a loss of US$0.24.
• Consensus narrative points to long term potential for margin improvement, yet these figures underline that earnings are still firmly negative, which sits awkwardly against expectations that profit margins could eventually move toward the broader US Medical Equipment industry average of around 12% while analysts are not forecasting profitability within the next three years.
  • Revenue has grown at about 10.3% per year over the last 12 months, but this pace comes alongside continuing losses, so growth is not yet translating into positive net income.
  • The five year trend of losses narrowing at about 7.6% per year is encouraging in the consensus story, but the latest trailing loss of US$37.3 million shows that any path toward that kind of margin profile would still be a long one.

10.3% revenue growth meets unprofitable outlook

• Revenue has grown about 10.3% per year over the last 12 months, slightly below the US market rate of 11.4%, while the company remains unprofitable and is expected in the supplied data to stay loss making over the next three years.
• Bulls argue that growing demand for minimally invasive eye care and potential reimbursement wins for TearCare could support stronger long term revenue and margin outcomes, yet the current figures give a mixed scorecard.
  • On the supportive side for the bullish view, trailing twelve month revenue of about US$79.6 million is higher than any individual quarter in the period provided, which fits with the idea of a larger underlying business base.
  • On the challenging side for that bullish case, forecasts in the data still point to the company remaining unprofitable over the next three years, so any optimistic scenario around future margins is not visible in reported earnings yet.

Bulls argue that the recent revenue trend and product positioning could eventually translate into stronger earnings power, but the current financials still show a company working through sizeable losses, so it can help to read the full bullish case alongside these numbers. 🐂 Sight Sciences Bull Case

P/S of 3.6x sits between industry and peers

• Sight Sciences trades on a P/S of 3.6x, which is higher than the broader US Medical Equipment industry average of 2.8x but below its peer group average of 4.1x, against a current share price of US$5.29.
• Bears focus on the combination of this mid range valuation, ongoing losses and recent insider selling as a warning that expectations may already be demanding for a business that is still unprofitable.
  • The trailing twelve month loss of US$37.3 million and basic EPS loss of US$0.71 mean the stock does not have a positive P/E to fall back on, so investors are leaning heavily on sales based metrics like P/S when judging value.
  • At the same time, the P/S of 3.6x is above the industry average despite forecasts indicating the company is expected to remain loss making over the next three years, which gives bears a clear numeric basis for arguing the stock is not obviously cheap relative to its current profitability profile.

Skeptics point out that paying above industry P/S for a company that is still reporting sizeable losses is a key tension in the cautious view, so it is worth comparing these valuation metrics with the detailed bear case before making any decisions. 🐻 Sight Sciences Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Sight Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seen enough to form a view, or still on the fence about the balance of risk and reward here? Act while the data is fresh in mind and pressure test the bullish and bearish points against the detailed breakdown of 1 key reward and 3 important warning signs

Explore Alternatives

Sight Sciences reports 10.3% revenue growth but still carries a US$37.3 million loss, negative EPS and a P/S premium to the broader medical equipment industry.

If you want stocks where pricing expectations look more grounded in current fundamentals, take a few minutes to scan the 51 high quality undervalued stocks today while this earnings update is fresh in mind.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.